309 related articles for article (PubMed ID: 17497445)
21. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F
Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928
[TBL] [Abstract][Full Text] [Related]
22. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis.
Ansari MR; Maheshwari N; Shaikh MA; Laghari MS; ; Lal K; Ahmed K
Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):21-5. PubMed ID: 22237213
[TBL] [Abstract][Full Text] [Related]
23. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial.
Bonomini M; Di Liberato L; Del Rosso G; Stingone A; Marinangeli G; Consoli A; Bertoli S; De Vecchi A; Bosi E; Russo R; Corciulo R; Gesualdo L; Giorgino F; Cerasoli P; Di Castelnuovo A; Monaco MP; Shockley T; Rossi C; Arduini A
Am J Kidney Dis; 2013 Nov; 62(5):929-38. PubMed ID: 23725973
[TBL] [Abstract][Full Text] [Related]
24. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients.
Amici G; Orrasch M; Da Rin G; Bocci C
Adv Perit Dial; 2001; 17():80-3. PubMed ID: 11510303
[TBL] [Abstract][Full Text] [Related]
25. Levels of plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis are not related to peritoneal losses of albumin.
Montenegro J; Moina I; Saracho R; González O; Martínez I; Esteban M
Nephron; 1997; 76(2):239-41. PubMed ID: 9200424
[No Abstract] [Full Text] [Related]
26. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients.
Cho KH; Do JY; Park JW; Yoon KW
Nephrol Dial Transplant; 2010 Feb; 25(2):593-9. PubMed ID: 19767632
[TBL] [Abstract][Full Text] [Related]
27. Is atherosclerosis accelerated by CAPD?
Kawaguchi Y; Kubo H; Yamamoto H; Nakayama M; Yokoyama K; Shigematsu T; Sakai O
Perit Dial Int; 1996; 16 Suppl 1():S223-30. PubMed ID: 8728197
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis.
Babazono T; Miyamae M; Tomonaga O; Omori Y
Adv Perit Dial; 1996; 12():120-5. PubMed ID: 8865885
[TBL] [Abstract][Full Text] [Related]
29. Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials.
Sniderman AD; Sloand JA; Li PK; Story K; Bargman JM
J Clin Lipidol; 2014; 8(4):441-7. PubMed ID: 25110226
[TBL] [Abstract][Full Text] [Related]
30. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass.
Brulez HF; van Guldener C; Donker AJ; ter Wee PM
Nephrol Dial Transplant; 1999 Jan; 14(1):154-9. PubMed ID: 10052496
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of the effect of icodextrin based peritoneal dialysis and hemodialysis on lipid metabolism.
Kadiroğlu AK; Ustündag S; Kayabaşi H; Yilmaz Z; Yildirım Y; Sen S; Yilmaz ME
Indian J Nephrol; 2013 Sep; 23(5):358-61. PubMed ID: 24049273
[TBL] [Abstract][Full Text] [Related]
32. Protein oxidative stress and dyslipidemia in dialysis patients.
Marques de Mattos A; Marino LV; Ovidio PP; Jordão AA; Almeida CC; Chiarello PG
Ther Apher Dial; 2012 Feb; 16(1):68-74. PubMed ID: 22248198
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
34. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism.
Bredie SJ; Bosch FH; Demacker PN; Stalenhoef AF; van Leusen R
Perit Dial Int; 2001; 21(3):275-81. PubMed ID: 11475343
[TBL] [Abstract][Full Text] [Related]
35. How to improve survival in geriatric peritoneal dialysis patients.
Hiramatsu M;
Perit Dial Int; 2007 Jun; 27 Suppl 2():S185-9. PubMed ID: 17556302
[TBL] [Abstract][Full Text] [Related]
36. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
37. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH).
de Moraes TP; Andreoli MC; Canziani ME; da Silva DR; Caramori JC; Ponce D; Cassi HV; de Andrade Bastos K; Rio DR; Pinto SW; Filho SR; de Campos LG; Olandoski M; Divino-Filho JC; Pecoits-Filho R
Nephrol Dial Transplant; 2015 Nov; 30(11):1905-11. PubMed ID: 26063787
[TBL] [Abstract][Full Text] [Related]
38. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
39. Evidence-based medicine in peritoneal dialysis: peritoneal dialysis solutions.
Feriani M
Contrib Nephrol; 2003; (140):202-8. PubMed ID: 12800361
[No Abstract] [Full Text] [Related]
40. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
